Nec Corporation

Juntendo Educational Foundation

Y's Ac Co., Ltd.

Taketo Yamada

Chikao Morimoto

Ryo Hatano

Yutaro Kaneko

Kei Ohnuma

Kohji Yamada

Mutsumi Hayashi

Toshihiro Okamoto

Mesothelioma growth inhibitory effect of standard cisplatin-pemetrexed concomitant therapy is potentiated by combination with an anti-CD26 antibody. A high therapeutic effect and excellent safety is obtained by the concomitant use of an anti-CD26 antibody and gemcitabine. By conjugating an anti-CD26 antibody (YS110) with triptolide via a divalent cross-linking agent for concomitant therapy using the anti-CD26 antibody, a novel antibody-drug conjugate (Y-TR1) very highly effective for CD26-positive malignant mesothelioma cells has been successfully obtained.

Cancer treatment composition combining anti-CD26 antibody and other anticancer agent

It is intended to provide an anti-human CD26 antibody which permits analysis, etc., of the expression of CD26 in cancer tissues, immune tissues, or the like, for example, in order to select a patient applicable to treatment or to monitor therapeutic effects, and can also be used in immunostaining. The present invention relates to an anti-human CD26 monoclonal antibody or an antigen-binding fragment thereof, binding to an epitope which is recognized by a monoclonal antibody produced by a hybridoma deposited under Accession No. NITE BP-01642, a hybridoma deposited under Accession No. NITE BP-01643, or a hybridoma deposited under Accession No. NITE BP-01644.

Anti-human CD26 monoclonal antibody or antigen-binding fragment thereof

A server system () in provided with: a first server () that operates in an active mode; and a plurality of second servers () that operate in a standby mode as a standby server for the first server (),

Server system, server, server control method, and non-transitory computer-readable medium containing server control program

Growing community of inventors

Tokyo, Japan

Taketo Yamada